Early Cancer Detection
Early Cancer Detection - Related Videos
08:45
Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
0 Views •
Cited by 8 •
2012
Use of Cerenkov Luminescence Imaging (CLI) for monitoring preclinical cancer treatment is described here. This method takes advantage of Cerenkov Radiation (CR) and optical imaging (OI) to visualize radiolabeled probes and thus provides an alternative to PET in preclinical therapeutic monitoring and drug screening.
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
0 Views •
2025
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded tissues.
06:08
Quantitative Visualization and Detection of Skin Cancer Using Dynamic Thermal Imaging
0 Views •
Cited by 69 •
2011
We demonstrated that malignant pigmented lesions with increased metabolic activity generate quantifiable amounts of heat and the measurement of the transient thermal response of the skin to a cooling excitation allows quantitative identification of melanoma and other skin cancers (vs. non-proliferative nevi) at an early stage of the disease.
08:09
Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
0 Views •
Cited by 11 •
2017
We explored a tubal cytologic method by sampling the fallopian tube directly post-surgical excision as a tool of ovarian cancer early detection. Here, we present a protocol to collect fallopian tube cells from freshly received surgical specimens.
09:57
Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples
0 Views •
Cited by 4 •
2017
Methods allowing the characterization and isolation of stem cell populations from biological samples are critical for the advance of stem cell-targeted treatments in cancer and beyond. Here, we provide a detailed protocol for cancer stem cell isolation using the dye-triggered side population phenotype.
FAQs
Early cancer detection relies on two linked but distinct decisions. Screening methods search for abnormal cells or cancer-associated signals, often before symptoms appear. When screening raises concern, diagnostic testing determines whether cancer is actually present. Keeping these roles separate helps clinicians avoid treating a preliminary signal as confirmed disease while still supporting timely intervention.
Imaging, molecular assays, biomarker analysis, and tissue examination provide different forms of evidence about possible cancer. These approaches can examine structural changes, molecular signals, measurable biological markers, or tissue findings. Their use supports broader assessment rather than reliance on a single type of observation, although no one approach is identified as universally superior.
Blood-based tests are an emerging approach intended to identify tumors earlier through cancer-associated signals found in blood. Their development reflects efforts to improve detection accuracy while minimizing unnecessary procedures. If these tests perform reliably, they could complement established screening strategies, but the overview presents them as an advancing technology rather than a replacement for diagnostic confirmation.
Findings from screening and follow-up diagnostic testing can contribute to risk assessment by clarifying whether cancer-associated evidence warrants further medical attention. Confirmed information may then support timely intervention and more informed treatment planning. This connection matters because detection is not an isolated laboratory goal; its clinical value depends on how results guide subsequent care.
A typical pathway begins with a screening method such as imaging, molecular analysis, biomarker assessment, or tissue examination. If the result suggests possible cancer, diagnostic testing follows to confirm disease. Confirmed findings can then inform risk assessment, intervention decisions, and treatment planning. This sequence separates initial detection from clinical confirmation and management.
Screening programs are particularly relevant when the goal is to identify cancer before symptoms develop. Earlier information can create an opportunity for timely intervention and may support more informed treatment planning. At a population or healthcare-system level, such programs also provide an organized framework for applying detection methods and evaluating their potential contribution to reducing cancer mortality.
Early cancer detection contributes to personalized care by supplying information that can shape risk assessment and treatment planning for an individual. Imaging, molecular assays, biomarker analysis, tissue examination, and emerging blood-based tests may provide complementary evidence for clinical decisions. Earlier, more accurate information can help align intervention and care planning with the patient’s documented disease status.